Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer (mCRPC) being presented during the 2021 ASCO Annual Meeting. Markowski, the lead study author and assistant professor of oncology at Johns Hopkins Medicine, also comments on where VERU-111 might fit in the mCRPC treatment sequence. (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056)
Enhancing the quality of bladder cancer care in the community setting
August 5th 2023Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.
BCAN session to highlight epigenetics and response to immunotherapy in bladder cancer
August 3rd 2023"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.
2 Clarke Drive
Cranbury, NJ 08512